Home › B-Cell Lymphoma › Missouri › Kansas City
B-Cell Lymphoma clinical trials in Kansas City, MO
5 studies for B-Cell Lymphoma are looking for participants at sites in and around Kansas City (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
RecruitingPhase 1/2
- The University of Kansas Cancer Center, Westwood · 5 mi away
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
RecruitingPhase 3
- University of Kansas Cancer Center, Westwood · 5 mi away
DALY II USA/ MB-CART2019.1 for DLBCL
RecruitingPhase 2
- University of Kansas Cancer Center, Westwood · 5 mi away
Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies
RecruitingPhase 1
- University of Kansas Cancer Center, Westwood · 5 mi away
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
RecruitingPhase 1/2
- University of Kansas, Westwood · 5 mi away
B-Cell Lymphoma trials in other cities
- New York City, NY18 studies
- Houston, TX16 studies
- Chicago, IL13 studies
- Nashville, TN11 studies
- Philadelphia, PA11 studies
- Rochester, MN10 studies
- Milwaukee, WI9 studies
- Baldwin Park, CA9 studies
- Cleveland, OH9 studies
- Boston, MA8 studies
- Salt Lake City, UT8 studies
- Washington, DC7 studies
Other studies in Kansas City
- Breast Cancer34 studies
- Non-Small Cell Lung Cancer31 studies
- Heart Failure25 studies
- Cancer (all types)21 studies
- Lung Cancer19 studies
- Colorectal Cancer16 studies
- Metastatic Cancer15 studies
- Acute Myeloid Leukemia15 studies
- Prostate Cancer14 studies
- Ovarian Cancer11 studies
- Obesity11 studies
- Type 2 Diabetes11 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.